Insilico Medicine Advances ISM6200 for Cancer Therapy
HONG KONG | April 10, 2026 Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
HONG KONG | April 10, 2026 Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1...
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...
SAN JOSE, Calif., Feb. 23, 2026 — Anixa Biosciences announced that immunology leader Jose Conejo-Garcia, M.D., Ph.D., will keynote...
SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian...
Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its...
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
